Search Result

Results for "

no obvious cytotoxicity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Antibiotic (1) Apoptosis (2) Bacterial (3) Carbonic Anhydrase (3) Cathepsin (1) Cholinesterase (ChE) (1) Dengue Virus (1) Drug Derivative (2) E1/E2/E3 Enzyme (2) Environmental Pollutants (1) ERK (1) Estrogen Receptor/ERR (3) Ferroptosis (1) FLT3 (1) HCV (1) HIF/HIF Prolyl-Hydroxylase (1) Influenza Virus (2) Insecticide (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) MicroRNA (1) Molecular Glues (2) NEDD8-activating Enzyme (2) NF-κB (1) NOD-like Receptor (NLR) (1) Nuclear Factor of activated T Cells (NFAT) (1) Orphan GPCR (1) Parasite (1) PCSK9 (1) RANKL/RANK (1) Reference Standards (1) SARS-CoV (1) TAM Receptor (1) TGF-beta/Smad (1) TGF-β Receptor (1) Virus Protease (3)
By Research Areas:	Cancer (9) Infection (9) Inflammation/Immunology (5) Metabolic Disease (4) Neurological Disease (5)

By Targets:

Androgen Receptor (1)

Antibiotic (1)

Apoptosis (2)

Bacterial (3)

Carbonic Anhydrase (3)

Cathepsin (1)

Cholinesterase (ChE) (1)

Dengue Virus (1)

Drug Derivative (2)

E1/E2/E3 Enzyme (2)

Environmental Pollutants (1)

ERK (1)

Estrogen Receptor/ERR (3)

Ferroptosis (1)

FLT3 (1)

HCV (1)

HIF/HIF Prolyl-Hydroxylase (1)

Influenza Virus (2)

Insecticide (1)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (1)

MicroRNA (1)

Molecular Glues (2)

NEDD8-activating Enzyme (2)

NF-κB (1)

NOD-like Receptor (NLR) (1)

Nuclear Factor of activated T Cells (NFAT) (1)

Orphan GPCR (1)

Parasite (1)

PCSK9 (1)

RANKL/RANK (1)

Reference Standards (1)

SARS-CoV (1)

TAM Receptor (1)

TGF-beta/Smad (1)

TGF-β Receptor (1)

Virus Protease (3)

By Research Areas:

Cancer (9)

Infection (9)

Inflammation/Immunology (5)

Metabolic Disease (4)

Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: WNK Kinase NO Synthase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128586

TAS4464 5+ Cited Publications	Apoptosis Carbonic Anhydrase NEDD8-activating Enzyme	Cancer
TAS4464 is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC₅₀=0.955 nM), and also inhibits CAII with an IC₅₀ of 0.73 μM, which is less potent than MLN4924 (HY-70062). The IC₅₀ values of TAS4464 against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 targets NEDD8 in an ATP-dependent manner to inhibit NAE, blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα), and further induces tumor cell apoptosis. TAS4464 exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 has a wide selcetive window, without obvious toxicity. TAS4464 can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.) .

HY-12494

LDC1267 Maximum Cited Publications 10 Publications Verification	TAM Receptor FLT3	Neurological Disease Cancer
LDC1267 is a AXL/TAM/FLT3 inhibitor with IC₅₀ values of 42 nM, 130 nM, and 63 nM against AXL, MERTK, and TYRO3, respectively. LDC1267 blocks GAS6-induced AXL phosphorylation and the downstream AKT/ERK1/2 signaling pathway. LDC1267 inhibits cancer cell proliferation, colony formation, and glioblastoma cell invasion, without causing obvious impairment of cytotoxic autophagic flux. LDC1267 exerts a synergistic effect when used in combination with Imatinib (HY-15463) in chronic myeloid leukemia models. LDC1267 can be widely applied in studies related to glioblastoma and chronic myeloid leukemia .

HY-128586A

TAS4464 hydrochloride 5+ Cited Publications	NEDD8-activating Enzyme Carbonic Anhydrase Apoptosis	Cancer
TAS4464 hydrochloride is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC₅₀=0.955 nM), and also inhibits CAII with an IC₅₀ of 0.73 μM, which is less potent than MLN4924 (HY-70062). The IC₅₀ values of TAS4464 hydrochloride against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 hydrochloride targets NEDD8 in an ATP-dependent manner to inhibit NAE, blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα), and further induces tumor cell apoptosis. TAS4464 hydrochloride exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 hydrochloride has a wide therapeutic window, without obvious toxicity. TAS4464 hydrochloride can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.) .

HY-162562

E28362	PCSK9	Metabolic Disease Inflammation/Immunology
E28362 is an orally active lipid-lowering agent and a selective PCSK9 antagonist. E28362 blocks the interaction between PCSK9 and LDLR, and induces PCSK9 degradation via the ubiquitin-proteasome pathway. E28362 significantly increases the levels of cell surface and total LDLR proteins, enhances low-density lipoprotein uptake, thereby effectively reducing plasma lipids, hepatic cholesterol and triglyceride levels. E28362 shows no obvious cytotoxicity at high concentrations, and significantly attenuates atherosclerotic lesions in animal models. E28362 is an important molecule in research of hyperlipidemia and atherosclerosis .

HY-146144

HIF-IN-1	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-IN-1 (Compound 3c) is a hypoxia-inducible factor (HIF)-1 inhibitor. HIF-IN-1 suppresses HIF-1α protein accumulation without affecting the levels of HIF-1α mRNA. HIF-IN-1 shows no obvious cytotoxicity .

HY-155417

GPR34 receptor antagonist 3	Orphan GPCR ERK	Neurological Disease
GPR34 receptor antagonist 3 (Compound 5e) is a class of GRP34 antagonists, IC₅₀ is 0.680 μM. GPR34 receptor antagonist 3 inhibited ERK1/2 phosphorylation induced by lysophosphatidylserine in a dose-dependent way without obvious cytotoxicity. GPR34 receptor antagonist 3 shows antisensory activity in mouse neuropathic pain model .

HY-136797

BP13944	Dengue Virus	Infection
BP13944 is a potential small molecule inhibitor discovered by high-throughput screening. It can effectively inhibit the expression of dengue virus (DENV) replicons with an EC50 value of 1.03±0.09 μM. BP13944 can inhibit the replication or viral RNA synthesis of all four serotypes of DENV, but is ineffective against Japanese encephalitis virus. BP13944 may target the DENV NS3 protease, and the E66G amino acid substitution in the NS3 protease region will cause the virus to become resistant to BP13944. BP13944 has no obvious cytotoxicity. As there is currently no effective dengue vaccine and treatment, BP13944, as an effective small molecule inhibitor, may become a potential agent for the treatment of dengue in the future.

HY-163641

AR Degrader-1	Molecular Glues Androgen Receptor E1/E2/E3 Enzyme	Cancer
AR Degrader-1 (Compound ML 2-9) is a molecular glue androgen receptor (AR) monovalent degrader. AR Degrader-1 degrades AR through DCAF16 (E3 ligase) without obvious cytotoxicity in LNCaP prostate cancer cells .

HY-156240

DI-1548	E1/E2/E3 Enzyme Keap1-Nrf2	Metabolic Disease
DI-1548 is a potent, selective, and irreversible covalent inhibitor of DCN1 (IC₅₀ = 4.6 nM). DI-1548 potently and selectively inhibits cullin 3 neddylation at nanomolar concentrations, and exhibits no obvious effect on the neddylation of other cullin members (including cullin 1, 2, 4A, 4B, and 5). DI-1548 exhibits no cytotoxicity. DI-1548 covalently binds to DCN1, disrupting the DCN1-UBC12 interaction, causing the collapse of the neddylation complex, inactivating CRL3, leading to NRF2 accumulation and upregulation of its target genes, and ultimately protecting mice from liver damage. DI-1548 can be used in liver injury research .

HY-146819

CAIX/CAXII-IN-1	Carbonic Anhydrase	Cancer
Compound 9 is the most effective against tumor specific Ca ix/ca XII (ki=29.1 and 8.8 nm), so it is possible to evaluate its cytotoxicity and selectivity to HepG-2, HCT-116 and MCF-7 cancer cell lines in vitro, and its IC₅₀ values to tumor cells are 1.78, 1.94 and 3.07, respectively μ M. It showed that it had obvious cytotoxicity.

HY-145842

Encephalitic alphavirus-IN-1	Virus Protease	Infection Neurological Disease
Encephalitic alphavirus-IN-1 has antiviral activity for VEEV and EEEV with EC₅₀s of 0.24 μM and 0.16 μM, respectively. Encephalitic alphavirus-IN-1 has robust mouse plasma stability, and no obvious cytotoxicity .

HY-N7980

Rubipodanone A	NF-κB	Cancer
Rubipodanone A, a naphthohydroquinone dimer, shows cytotoxicity against A549, BEL-7402, HeLa, HepG2, SGC-7901 and U251 cells. Rubipodanone A also shows obvious activating effect at 20 and 40 μM for NF-κB .

HY-163695

NLRP3-IN-41	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-41 (compd S-9) is an orally active and brain-penetrant NLRP3 inhibitor with anti-inflammatory activities, anti-neuroinflammatory effect and without obvious cytotoxicity. NLRP3-IN-41 inhibits the priming and activation stages of the NLRP3 inflammasome and can be used for inflammasome-related diseases research .

HY-177731

MG-Lin1	Molecular Glues MicroRNA	Cancer
MG-Lin1 is a molecular glucose degrading agent that targets the Lin28 protein. MG-Lin1 can significantly reduce the mRNA levels of let-7 targeting oncogenes. MG-Lin1 can significantly inhibit the migration ability of cancer cells. MG-Lin1 has no obvious cytotoxicity. MG-Lin1 can be used for cancer research .

HY-P11227

Compound 19A8.8	TGF-β Receptor TGF-beta/Smad	Neurological Disease
Compound 19A8.8 is a cyclic peptide derived from a CD36 protein fragment. Compound 19A8.8 inhibits the TGF-β/Smad3 signaling pathway by suppressing the interaction between TSP1 and CD36. Compound 19A8.8 has no obvious cytotoxicity. Compound 19A8.8 can be used for research on colon injury and fibrosis .

HY-149263

HAA-09	Influenza Virus Virus Protease	Infection
HAA-09 is an orally active and potent anti-influenza agent, targeting the influenza PB2_cap binding domain. HAA-09 displays potent anti-influenza A virus activity, with an EC₅₀ of 0.03 μM. HAA-09 shows polymerase inhibition, with an IC₅₀ of 0.06±0.004 μM. HAA-09 blocks virus replication without causing obvious cytotoxicity .

HY-149719

Ferroptosis-IN-4	Ferroptosis	Metabolic Disease
Ferroptosis-IN-4 (compound 6k) is a ferroptosis inhibitor with EC₅₀ value of 20 μM. Ferroptosis-IN-4 has no obvious cytotoxicity. Ferroptosis-IN-4 has a protective effect in glycerol-induced RM-AKI mice with alleviating kidney dysfunction .

HY-115969

F-17	Bacterial	Infection
F-17 is a potential inhibitor of virulence factor. F-17 shows very significant inhibitory effect on biofilm, elastase, pyocyanin, and swarming motility. F-17 also shows a good binding effect on LasR and PqsR. F-17 has no obvious cytotoxicity .

HY-P10858

UCI-1	SARS-CoV Virus Protease	Infection
UCI-1 is a SARS-CoV-2 main protease (M ^pro) cyclic peptide inhibitor with an IC₅₀ of 160 μM. UCI-1 shows no obvious cytotoxicity at the concentration of inhibiting M ^pro. UCI-1 can be used in the study of anti-COVID-19 drugs .

HY-W009160S

Octrizole-d4 UV-329-d₄	Isotope-Labeled Compounds Estrogen Receptor/ERR	Others
Octrizole-d₄ (UV-329-d₄) is deuterium labeled Octrizole (HY-W009160) . Octrizole (UV-329) is a UV screener/stabilizer. Octrizole can prevent products from yellowing and degradation. Octrizole exhibits significant cytotoxicity to MVLN cells at concentrations higher than 50 μM and has no obvious estrogenic activity.

HY-177299

HCV NS5B polymerase-IN-3	HCV	Infection
HCV NS5B polymerase-IN-3 (Compound 30a) is an inhibitor of the HCV NS5B polymerase. HCV NS5B polymerase-IN-3 exhibits anti-HCV activity in the Huh7 replicon cell line with an EC₅₀ of 0.23 μM and shows no obvious cytotoxicity. HCV NS5B polymerase-IN-3 can be used in research related to the hepatitis C virus .

HY-146001

Influenza virus-IN-4	Influenza Virus	Inflammation/Immunology
Influenza virus-IN-4 (compound 11e) is a potent influenza virus neuraminidase inhibitor with IC₅₀s of 3.4, 0.094, 0.79, 0.077 µM for H5N1, H5N2, H5N6, H5N8, respectively. Influenza virus-IN-4 shows NA (neuraminidase enzyme)-inhibitory activity. Influenza virus-IN-4 shows low cytotoxicity with an CC₅₀ of >200 µM. Influenza virus-IN-4 shows no obvious toxicity at the dose of 1500 mg/kg in mice .

HY-181119

AChE-IN-106	Cholinesterase (ChE)	Neurological Disease
AChE-IN-106 is an AChE inhibitor. AChE-IN-106 shows no obvious cytotoxicity at low concentrations. AChE-IN-106 can be used for the research of Alzheimer's disease .

HY-W009160

Octrizole UV-329	Environmental Pollutants Estrogen Receptor/ERR	Others
Octrizole (UV-329) is a UV screener/stabilizer. Octrizole can prevent products from yellowing and degradation. Octrizole exhibits significant cytotoxicity to MVLN cells at concentrations higher than 50 μM and has no obvious estrogenic activity .

HY-N19720

Bractein	Drug Derivative Parasite	Infection
Bractein is a natural aurone flavonoid with potential antioxidant activity. Bractein shows in vitro antileishmanial activity and inhibits promastigotes and intracellular amastigotes of Leishmania donovani. Bractein exhibits no obvious cytotoxicity against mammalian macrophages with an EC₅₀ value > 25.0 μg/mL. Bractein can be used for the research of Leishmania .

HY-W009160R

Octrizole (Standard) UV-329 (Standard)	Reference Standards Estrogen Receptor/ERR	Others
Octrizole (Standard) (UV-329 (Standard)) is the analytical standard of Octrizole (HY-W009160). This product is intended for research and analytical applications. Octrizole (UV-329) is a UV screener/stabilizer. Octrizole can prevent products from yellowing and degradation. Octrizole exhibits significant cytotoxicity to MVLN cells at concentrations higher than 50 μM and has no obvious estrogenic activity.

HY-180810

T504	Antibiotic Bacterial	Infection
T504 is an oxazolidinone antibiotic. T504 exhibits significant growth inhibitory effects on Mycobacterium tuberculosis H37Rv, Mycobacterium bovis BCG, and Mycobacterium abscessus, and the MIC value for the reference strain Mycobacterium tuberculosis H37Rv is 0.5-1.0 μg/mL. T504 effectively inhibits the growth of Mycobacterium tuberculosis within macrophages and does not show obvious cytotoxicity. T504 can be used in the research of mycobacterial infections .

HY-W753557

Avocadene	Drug Derivative Insecticide Bacterial	Infection Inflammation/Immunology Cancer
Avocadene is a natural product isolated from Persea americana leaves, with anticancer, insecticidal, anti-Helicobacter pylori, and anti-inflammatory activity. Avocadene exerts antibacterial and anti‑inflammatory effects by suppressing Helicobacter pylori growth and inhibiting protein denaturation. Avocadene displays obvious cytotoxic activity against human prostate cancer PC‑3 cells with an IC₅₀ of 0.5 μg/mL. Avocadene can be used for research of Helicobacter pylori‑associated gastrointestinal inflammation, gastroduodenal injury and prostate tumors .

HY-182757

Y1693	RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Cathepsin	Metabolic Disease Inflammation/Immunology
Y1693 is an orally active RANKL inhibitor with a K_d of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases .

Cat. No.	Product Name	Target	Research Area